Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Kissei Snares Rigel’s AML Therapy in Japan, Korea, Taiwan
Kissei Pharmaceutical said on September 4 that it has grabbed the exclusive rights to US biotech partner Rigel Pharmaceuticals’ investigational acute myeloid leukemia (AML) drug olutasidenib in Japan, South Korea, and Taiwan. Under their agreement, the Japanese company will exclusively…
To read the full story
Related Article
- Kissei Files Rigel’s AML Drug Olutasidenib in Japan
May 28, 2026
- Kissei Sublicenses Taiwan Rights for Rigel’s AML Drug to OEP
May 11, 2026
- Tavalisse Now Available in South Korea for Chronic ITP: Kissei
July 2, 2025
- ITP Drug Tavalisse Approved in South Korea: Kissei
January 22, 2025
- Kissei’s ITP Med Tavalisse Now Available in Japan
April 7, 2023
BUSINESS
- Regeneron Japan Files First Dual-AAV Therapy for Genetic Hearing Loss
July 30, 2026
- Leqembi Global Sales Rise to 29.3 Billion Yen in April-June: Eisai
July 30, 2026
- Some Drug Plants Halt Operations after Kumamoto Temblor, Supplies Unaffected
July 30, 2026
- MSD Urges Swift Rollout of Routine HPV Vaccination for Males in Japan
July 29, 2026
- Drug Makers, Wholesalers Rush to Gauge Kumamoto Quake Impact
July 29, 2026
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…